A Biphasic COVID-19 Clinical Course in Anti-CD20 Treated Patients: Case Series and Review of the Literature
  • Noa Bigman-Peer
    Department of Internal Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
  • Eyal Peer
    Oncology Institute, Sheba Medical Center, Ramat Gan, Israel
  • Barak Pertzov
    Pulmonary Division, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
  • Mordechai Kramer
    Pulmonary Division, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Gad Segal
    Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Internal Medicine I, Sheba Medical Center, Ramat Gan, Israel
  • Noa Eliakim-Raz
    Department of Internal Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel

Keywords

COVID-19, anti-CD20, rituximab, obinutuzumab, Omicron

Abstract

We describe four cases of COVID-19 infection during the Omicron wave, in patients treated with anti-CD20 monoclonal antibodies. All cases follow a similar biphasic clinical course consisting of respiratory deterioration, which occurred a few weeks after convalescence from initial mild to asymptomatic infection. Possible explanations are discussed.

VIEW THE ENTIRE ARTICLE

References

  • Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P, Porta-Etessam J, Pytel V, Matias-Guiu JA. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain. Mult Scler Relat Disord 2020;42:102185.
  • Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol 2021;3(6):e419–26.
  • Leipe J, Wilke EL, Ebert MP, Teufel A, Reindl W. Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab. Semin Arthritis Rheum 2020;50(5):1087–8.
  • Burgener S, Rochat P, Dollenmaier G, Benz G, Kistler AD, Fulchini R. Progression of COVID-19 in a patient on anti-CD20 antibody treatment: case report and literature review. Case Rep Infect Dis 2022;2022.
  • Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021;184(4):861–80.

    • Views: 554
    HTML downloads: 189
    PDF downloads: 268

    Published: 2022-08-31
    Issue: 2022: Vol 9 No 8 (view)

    How to cite:
    1.
    Bigman-Peer N, Peer E, Pertzov B, Kramer M, Segal G, Eliakim-Raz N. A Biphasic COVID-19 Clinical Course in Anti-CD20 Treated Patients: Case Series and Review of the Literature. EJCRIM 2022;9 doi:10.12890/2022_003502.